Royal Free London NHS Foundation Trust

London, England NW32QG

1 studies enrolling now · 8 studies all time

What they study most

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, Cirrhosis, Liver, Critical Illness, Enteral Feeding Intolerance, Enteral Nutrition, Hepatitis C, Chronic, NASH, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Rheumatoid Arthritis

Studies at this site

• A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. — Recruiting now
• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) — Running, not enrolling
• A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Completed
• A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis — Running, not enrolling
• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) — Stopped early
• Gilead Sustained Virologic Response (SVR) Registry — Completed